TITLE

Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins

AUTHOR(S)
Tenenbaum, Alexander; Fisman, Enrique Z.; Motro, Michael; Adler, Yehuda
PUB. DATE
January 2006
SOURCE
Cardiovascular Diabetology;2006, Vol. 5, p20
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Lowering of low-density lipoprotein cholesterol with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) is clearly efficacious in the treatment and prevention of coronary artery disease. However, despite increasing use of statins, a significant number of coronary events still occur and many of such events take place in patients presenting with type 2 diabetes and metabolic syndrome. More and more attention is being paid now to combined atherogenic dyslipidemia which typically presents in patients with type 2 diabetes and metabolic syndrome. This mixed dyslipidemia (or "lipid quartet"): hypertriglyceridemia, low high-density lipoprotein cholesterol levels, a preponderance of small, dense low-density lipoprotein particles and an accumulation of cholesterol-rich remnant particles (e.g. high levels of apolipoprotein B) - emerged as the greatest "competitor" of low-density lipoprotein-cholesterol among lipid risk factors for cardiovascular disease. Most recent extensions of the fibrates trials (BIP - Bezafibrate Infarction Prevention study, HHS - Helsinki Heart Study, VAHIT - Veterans Affairs High-density lipoprotein cholesterol Intervention Trial and FIELD - Fenofibrate Intervention and Event Lowering in Diabetes) give further support to the hypothesis that patients with insulin-resistant syndromes such as diabetes and/or metabolic syndrome might be the ones to derive the most benefit from therapy with fibrates. However, different fibrates may have a somewhat different spectrum of effects. Other lipid-modifying strategies included using of niacin, ezetimibe, bile acid sequestrants and cholesteryl ester transfer protein inhibition. In addition, bezafibrate as pan-peroxisome proliferator activated receptor activator has clearly demonstrated beneficial pleiotropic effects related to glucose metabolism and insulin sensitivity. Because fibrates, niacin, ezetimibe and statins each regulate serum lipids by different mechanisms, combination therapy - selected on the basis of their safety and effectiveness - may offer particularly desirable benefits in patients with combined hyperlipidemia as compared with statins monotherapy.
ACCESSION #
28682806

 

Related Articles

  • Triglycerides, apo C3 and Lp B:C3 and cardiovascular risk in Type II diabetes. Gervaise, N.; Garrigue, M. A.; Lasfargues, G.; Lecomte, P. // Diabetologia;Jun2000, Vol. 43 Issue 6, p703 

    Aims/hypothesis. Cardiovascular complications and particularly coronary heart disease are the main causes of morbidity and mortality in Type II (non-insulin-dependent) diabetes mellitus. Some studies have shown that hypertriglyceridaemia in diabetes is an independent cardiovascular risk factor....

  • Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Kathiresan, Sekar; Melander, Olle; Guiducci, Candace; Surti, Aarti; Burtt, Noël P.; Rieder, Mark J.; Cooper, Gregory M.; Roos, Charlotta; Voight, Benjamin F.; Havulinna, Aki S.; Wahlstrand, Björn; Hedner, Thomas; Corella, Dolores; Tai, E. Shyong; Ordovas, Jose M.; Berglund, Göran; Vartiainen, Erkki; Jousilahti, Pekka; Hedblad, Bo; Taskinen, Marja-Riitta // Nature Genetics;Feb2008, Vol. 40 Issue 2, p189 

    Blood concentrations of lipoproteins and lipids are heritable risk factors for cardiovascular disease. Using genome-wide association data from three studies (n = 8,816 that included 2,758 individuals from the Diabetes Genetics Initiative specific to the current paper as well as 1,874 individuals...

  • European society issues guidelines on cardiovascular disease. Mayor, Susan // BMJ: British Medical Journal (International Edition);9/6/2003, Vol. 327 Issue 7414, p518 

    Examines new European guidelines which extend recommendations for the prevention of coronary heart disease to cardiovascular disease and advise more aggressive interventions in high risk patients. Highlights of the new guidelines which include coverage of atherosclerotic cardiovascular disease...

  • Diabetes and Coronary Risk Equivalency. Grundy, Scott M. // Diabetes Care;Feb2006, Vol. 29 Issue 2, p457 

    Comments on a study which reported the incidence of coronary heart disease in type 2 diabetes patients in southwestern Oklahoma, central Arizona and North and South Dakota. Review of related studies; Discussion on the research findings; Approach proposed by the National Cholesterol Education...

  • Atorvastatin reduced risk for major CV events in patients with CAD, CKD, diabetes. Blumenthal, Roger S. // Endocrine Today;10/10/2008, Vol. 6 Issue 18, p18 

    The article discusses research on the impact of lipid-lowering with high-dose atorvastatin on the risk for major cardiovascular events in patients with coronary artery disease, type 2 diabetes and chronic kidney disease (CKD). Results showed that patients with diabetes and CKD assigned to...

  • Improved Plaque Stability and Reduced Inflammation during Pioglitazone Treatment in Type 2 Diabetic Patients with CHD. Forst, Thomas; Lübben, Georg; Mushold, Petra; Karagiannis, Efstrathios; Kann, Peter; Pfützner, Andreas // Diabetes;Jun2007 Supplement 1, Vol. 56, pA172 

    Inflammation and plaque instability are important mediators of cardiovascular risk in patients with diabetes mellitus type 2. Matrix metalloproteinase 9 (MMP-9) is critically involved in plaque rupture and acute coronary syndromes. We investigated MMP-9 levels and inflammatory markers during...

  • The Determination of Cardiovascular Risk Factor Profiles in Type 1 Diabetes. Pambianco, Georgia; Costacou, Tina; Orchard, Trevor // Diabetes;Jun2007 Supplement 1, Vol. 56, pA176 

    To determine if the risk factor profile differs in persons with type 1 diabetes (T1D) who develop coronary artery disease (CAD) from that of people who develop lower extremity arterial disease (LEAD) or both LEAD and CAD, 16 year follow up data were examined from the Pittsburgh Epidemiology of...

  • Long-Term Cardiovascular Risk in Type 2 Diabetic Compared With Nondiabetic First Acute Myocardial Infarction Patients. CANO, J. FRANCISCO; BAENA-DIEZ, JOSE M.; FRANCH, JOSEP; VILA, JOAN; TELLO, SUSANA; SALA, JOAN; ELOSUA, ROBERTO; MARRUGAT, JAUME // Diabetes Care;Sep2010, Vol. 33 Issue 9, p2004 

    OBJECTIVE -- The aim of this study was to determine whether long-term cardiovascular risk differs in type 2 diabetic patients compared with first acute myocardial infarction patients in a Mediterranean region, considering therapy, diabetes duration, and glycemic control. RESEARCH DESIGN AND...

  • Diabetes and your heart.  // Prevention India;Apr2011, p6 

    The article reports that cardiovascular disease (CVD) is the commonest cause of death in people with type 2 diabetes. According to the International Diabetes Federation, more than 30 percent of type 2 diabetics will have co-existent coronary heart disease and this shows that diabetes increases...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics